| First Author | Dong Y | Year | 1999 |
| Journal | Int J Cancer | Volume | 81 |
| Issue | 6 | Pages | 930-8 |
| PubMed ID | 10362141 | Mgi Jnum | J:55188 |
| Mgi Id | MGI:1337466 | Doi | 10.1002/(sici)1097-0215(19990611)81:6<930::aid-ijc15>3.0.co;2-a |
| Citation | Dong Y, et al. (1999) Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers. Int J Cancer 81(6):930-8 |
| abstractText | Decreased gelsolin and increased cyclin D1 are among the most common defects found in human and rodent breast cancers. Our purpose was to determine the frequency of concurrence of these 2 alterations in this malignancy. Our results demonstrate that gelsolin protein and mRNA were significantly reduced in 80-100% of rodent mammary carcinomas that developed spontaneously, following oncogene introduction, or after treatment with viral, chemical or hormonal agents. The reduction in gelsolin most likely occurs during the transition from preneoplasia to carcinoma because hyperplasias had normal levels of gelsolin whereas microtumors had reduced expression. Southern analysis revealed no major mutations in the gelsolin gene of tumors with low expression. Cyclin D1 mRNA was increased in 50-100% of these rodent mammary tumors, although the cyclin D1 gene was not amplified. By nuclear runon assay, downregulation of gelsolin in both human and mouse mammary cancer cells involved diminished transcription and, conversely, human breast cancer cells expressing high levels of cyclin D1 had increased initiation of cyclin D1 transcription compared with cyclin D1 low expressors. Thus, alteration in the rate of transcription appears to be an important factor underlying the dysfunction of these genes. According to our data, concurrent deregulation of gelsolin and cyclin D1 is highly prevalent among breast cancers of humans and rodents, with both defects present in 89% of the neoplasms analyzed in this study. In fact, most tumors in every rodent model of mammary tumorigenesis examined had the 2 alterations. |
